Search Results - "An, Xiaoyu (Annie)"

12 Development of an in vitro assay to assess bispecific T cell engager using T cells from CD3e humanized mice by Zhou, Jun, Zhu, Shuang, Zhang, Hongjuan, Zheng, Lei, Zang, Mingfa, An, Annie Xiaoyu, Wang, Shuzong, Ouyang, Davy Xuesong, Li, Henry, Huang, Yujun

“…BackgroundBispecific T cell engagers (BiTE) is a fast-growing class of immunotherapies. They are bispecific antibody that bind to T cell-surface protein (for…”
Get full text

237 In vitro potency assays for immune checkpoint blockade using human primary cells, murine huGEMM immune cells and patient-derived tumor organoids by Yan, Xuefei, Zhang, Hongjuan, Zhou, Jun, Zheng, Jia, Zhu, Shuang, Zhang, Rui, Zang, Mingfa, An, Annie Xiaoyu, Xu, Xiaoxi, Wang, Shuzong, Xu, Kevin Qijin, Ouang, Davy Xuesong, Li, Henry, Huang, Yujun

“…BackgroundThe demand of evaluating potency of immune checkpoint modulators is steadily growing for immune-oncology drug development.MethodsWe aimed to…”
Get full text

527 Tumor organoid and immune cell co-culture system potentiates immuno-oncology drug development by Zhang, Hongjuan, Zhou, Jun, Zhu, Shuang, Zheng, Jia, Shang, Limei, Li, Chunmei, Yan, Xuefei, Zhang, Rui, Zang, Mingfa, An, Annie Xiaoyu, Xu, Xiaoxi, Wang, Shuzong, Li, Henry, Huang, Yujun

“…BackgroundPatient-derived organoids (PDOs) are derived from adult epithelial stem cell with self-renewal, organisation and differentiation properties,…”
Get full text

Abstract 1503: Effect of immune cell depletion on the responses to PD1 treatment in syngeneic models by Jin, Ying, Shan, Yongli, An, Annie Xiaoyu, Li, Henry Qixiang, Ouyang, Davy Xuesong

“…Abstract Immunological checkpoint inhibitors, i.e., PD1 or PD-L1 antibodies, reverse cancer immunosuppression and promote antitumor immune responses in several…”
Get full text

Abstract 4621: Developing genetically modified homograft models of mouse prostate cancer for efficacy evaluation of combinatory immunotherapies by Wang, Jessie Jingjing, Song, Yanrui, An, Annie Xiaoyu, Zhang, Likun, Li, Henry Qixiang, Ouyang, Davy Xuesong

“…Abstract Despite the early approval of Sipuleucel-T for metastatic castration-resistant prostate cancer, which often perceived as a milestone achievement in…”
Get full text

Abstract C102: Investigation of the mechanism of action of anti-PD-1 treatment by systematic depletion of different immune cell populations in syngeneic models by Jin, Ying, Shan, Yongli, An, Annie Xiaoyu, Li, Henry Qixiang, Ouyang, Davy Xuesong

“…Abstract Background: Human cancers are heterogenic and thus response to immune checkpoint inhibitors (ICIs) such as anti-PD-1 or anti-PD-L1 antibody treatments…”
Get full text

Abstract 5616: Characterization of a spectrum of DTR models for conditional depletion of specific immune cell lineages by Jin, Ying, Zhou, Jiahua, Li, Fengge, Sun, Ruilin, An, Annie Xiaoyu, Li, Henry Q. X., Ouyang, Davy Xuesong

“…Abstract Introduction: Cancer immunotherapy often works through more than one mechanism of action (MOA) mediated by multiple immune cell subsets. We have…”
Get full text

Abstract 5615: Anti-human CD47 antibody Hu5F9 inhibits MC38 tumor growth in hCD47/hSIRPα double knock-in mice by He, Daniel Xianfei, Nie, Chenpan, Zheng, Lei, Sun, Ruilin, An, Annie Xiaoyu, Li, Henry Q. x., Ouyang, Davy Xuesong

“…Abstract Introduction: CD47 is broadly expressed on all normal cells or tissues, such as hematopoietic cells, T cells, B cells, monocytes, thymocytes, and…”
Get full text

Abstract 502: In vitro characterization of antibodies targeting the SIRPα-CD47 phagocytosis checkpoint using tumor-associated macrophages from HuGEMM™ mice by Yan, Xuefei, Zhang, Hongjuan, Liu, Yi, Zhang, Yahong, Zheng, Lei, Zang, Mingfa, An, Annie Xiaoyu, Xu, kevin Qijin, Ouyang, Davy, Li, Henry, Huang, Yujun

“…Abstract Introduction: The signal-regulatory protein SIRPα-CD47 pathway is a phagocytosis checkpoint for macrophages and other innate immune cells. Tumor cells…”
Get full text

Abstract 4976: Ex vivo functional characterization and in vivo efficacy validation of human CD40 agonistic antibodies in the human CD40 knock-in model (CD40 HuGEMM) by He, Daniel Xianfei, Zheng, Lei, Sun, Ruilin, An, Annie Xiaoyu, Fei, Jian, Li, Henry Qixiang, Ouyang, Davy Xuesong

“…Abstract CD40 receptor is a member of TNF-receptor superfamily, broadly expressed on the surface of antigen-presenting cells (APC) including B cells, dendritic…”
Get full text

Abstract 2375: Developing double knock-in models of human immune checkpoint targets (dKI HuGEMM) for efficacy assessment of combinatorial therapeutic antibodies by Zheng, Lei, He, Daniel Xianfei, Sun, Ruilin, An, Annie Xiaoyu, Fei, Jian, Li, Henry Qixiang, Ouyang, Davy Xuesong

“…Abstract Immune checkpoint inhibitors (ICIs), i.e. PD1, PDL1 and CTLA4 therapeutic antibodies, have led to long-term survival in many late stage solid tumor…”
Get full text

Abstract A010: Development of OVA-expressing immunogenic syngeneic mouse tumor models: CT26-OVA and B16-OVA by Jin, Ying, Wang, Phillip Shuzong, Li, Zhongliang, An, Annie Xiaoyu, Zhou, Jiahua, Li, Henry Qixiang, Ouyang, Davy Xuesong

“…Abstract Background: Syngeneic homograft mouse tumor models have been the workhorse for investigating immuno-oncology (I/O) therapeutics. However, there are…”
Get full text

Abstract 5614: Combination of anti-TIGIT and anti-PD-1 antibodies enhance antitumor response in a PD-1/TIGIT double HuGEMM™ model engrafted with mouse syngeneic tumors by He, Daniel Xianfei, Nie, Chenpan, Zheng, Lei, Sun, Ruilin, Zhang, Mingkun, An, Annie Xiaoyu, Ju, Cunxiang, Li, Henry Q. X., Ouyang, Davy Xuesong

“…Abstract Introduction: Ample clinical and preclinical evidence have shown the remarkable antitumor effects of anti-PD-1 antibodies. However, the fact that only…”
Get full text

Abstract 1144: Building Kras (G12D)/Trp53 null/Pdx1-cre (KPC) mouse allograft tumor model for efficacy evaluation of combinatory immunotherapies by Song, Yanrui, Liu, Benqi, An, Annie Xiaoyu, Zhang, Likun, Cai, Jie, Shi, Qian, Li, Henry Qixiang, Ouyang, Davy Xuesong

“…Abstract Pancreas ductal adenocarcinoma (PDAC) has dreadful 5-year survival of 6% and remains one of the most difficult to treat cancers with very few…”
Get full text

Abstract 5118: STING agonist and TLR7/8 agonist overcome anti-PD-1 resistance mediated by loss of β2M by Hua, Li, Nie, Chenpan, Lin, Jie, An, Annie Xiaoyu, Bourre, Ludovic, Wang, Jingjing

“…Abstract Introduction: PD-1 blockade has achieved great success in the clinic. However, only a small subset of patients benefits from the treatment and most…”
Get full text

Abstract A207: Utilizing human OX40 knock-in mice (HuGEMMTM) to assess antitumor efficacy of OX40-agonistic antibodies by Huang, Xuesong, Zheng, Lei, Ouyang, Wenyi, Zhang, Mingkun, An, Annie Xiaoyu, Zhao, Jing, Gao, Xiang, Wery, Jean Pierre, Shi, Qian

“…Abstract OX40 is a costimulatory molecule of TNF receptor family, primarily expressed on activated effector T cells and regulatory T cells. Engagement of OX40…”
Get full text

Abstract A003: Developing an AML mouse syngeneic model for combinatory chemotherapy and immunotherapy by Tang, Xin, Tong, Lily, An, Annie Xiaoyu, Zhang, Likun, Cai, Jie, Shi, Qian, Wery, Jean Pierre, Ouyang, Davy Xuesong

“…Abstract Little progress has been made in treatment of acute myeloid leukemia (AML) for years. Following the success of immune checkpoint inhibitors in solid…”
Get full text

Abstract 2807: Developing a variety of primary mouse tumor allograft models for evaluating efficacy of PARP inhibitor by Qu, Gavin Jiagui, Ouyang, Davy Xuesong, Chen, Li, Zhang, Likun, An, Annie Xiaoyu, Cai, Jie, Li, Henry Q. X.

“…Abstract Recent success of multiple poly (adenosine diphosphate [ADP]) ribose polymerase inhibitors (PARPi) in treating BRCA mutant ovarian cancers has fueled…”
Get full text

Abstract 5669: Establishment of a human CD3ε transgenic mouse model to assess anti-tumor efficacy of human T-cell-redirecting bispecific antibodies by Yang, Mengmeng, Zhang, Mingkun, Verploegen, Sandra, Engelberts, Patrick, Zhang, Yuxi, Zheng, Lei, Zhu, Keyi, An, Annie Xiaoyu, Ju, Cunxiang, Zhao, Jing, Gao, Xiang, Shi, Qian, Ouyang, Davy Xuesong

“…Abstract T-cell redirecting therapy has taken a prominent area in immuno-oncology. T cells driven by a tumor-specific antigen, traffic into the tumor and…”
Get full text

Abstract 4168: BALB/c-CD3EDG HuGEMMTM mouse model for evaluation of CD3-targeted tumor immunotherapy by Liu, Demi Xiaojuan, Lian, Kaixia, Yan, Xuefei, Lin, Jie, Zheng, Lei, Xiaoyu An, Annie, Xu, Xiaoxi, Bourre, Ludovic, Wang, Jingjing

“…Abstract Introduction: T cell immune response plays critical roles in cancer immunotherapy. CD3 complex, composed of CD3ε, CD3δ and CD3γ chains, is an…”
Get full text